Back to start page
Programme Sessions
The sessions covered key issues along the road from discovery
to
routine production, rather than specific plasma products, and
was based on
papers submitted for oral and poster presentations.
Each main session was developed by the chairman based on the
issues
participants consider most important for their work. This approach
ensured that
PPB 2001 dealt with the topics that matter today. Special emphasis
was also placed on poster presentations and informal discussions.
There was ample
opportunity for participants to meet and exchange views outside
of the confines of
the lecture room.
View the final programme
In the evening of Monday May 14th our keynote speaker, Professor Juhani Leikola, gave a lecture entitled “Past, present and future directions in plasma protein biotechnology”.
The programme covered the following themes with invited chairmen as indicated.
|
Session |
Chairman |
Affiliation |
|---|---|---|
|
Research and novel technologies |
Jan Over |
Sanquin Blood Supply Foundation, The Netherlands |
| Development | David Naveh | Bayer Corp., USA |
| Clinical aspects | Darryl Maher | CSL Ltd., Australia |
|
Regulatory perspectives |
Albert Farrugia |
Therapeutic Goods Administration, Australia |
| Manufacturing | Johan Vandersande | Baxter Healthcare Corp., USA |
| Safety considerations | Bernard Horowitz | New York, USA |